DCTH
What one share of Delcath Systems holds
Surgical and Medical Instruments and Apparatus
We are an interventional oncology company focused on the treatment of cancers primary or metastatic to the liver.
Delcath Systems’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.40 |
|---|---|
| Profit | $0.01 |
| Capex (buildings and equipment) | $0.05 |
| Free cash flow | $0.44 |
| Cash and investments | $1.37 |
| Book value | $3.50 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$8.35 | $0.27 | −$8.16 | — | — |
| 2021 | $0.50 | −$3.59 | $0.02 | −$3.18 | — | $1.51 |
| 2022 | $0.31 | −$4.12 | $0.02 | −$2.84 | — | −$0.58 |
| 2023 | $0.13 | −$2.94 | $0.00 | −$1.93 | — | $0.69 |
| 2024 | $1.30 | −$0.93 | $0.02 | −$0.67 | — | $2.08 |
| 2025 | $2.14 | $0.07 | $0.04 | $0.53 | — | $3.21 |